Exercise

Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering

Retrieved on: 
Thursday, March 28, 2024
Failure, Madison Avenue, Exercise, Fibromyalgia, Infection, Cocaine, Autoimmunity, Central nervous system, Form, Telephone, Patient, CNS, Research, Sale, NDA, Disease, Cancer, Long, Security (finance), Breakthrough therapy, Nature, Risk, Annual report, Therapy, Series, CD40L, FDA, Sumatriptan, Government, Food

The closing of the offering is expected to take place on or about April 1, 2024, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to take place on or about April 1, 2024, subject to the satisfaction of customary closing conditions.
  • The gross proceeds of the offering will be approximately $4.4 million before deducting placement agent fees and other estimated offering expenses payable by the Company.
  • A.G.P./Alliance Global Partners is acting as sole placement agent for the offering.
  • This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No.

Abaxx Announces Closing of C$18,687,500 Bought Deal Financing Including Full Exercise of Over-Allotment Option

Retrieved on: 
Thursday, March 28, 2024
Indian stock exchange, Exercise, Offering, Podcast, Regulation, BMO Capital Markets, CBOE, Person, Security (finance)

TORONTO, March 28, 2024 (GLOBE NEWSWIRE) -- Abaxx Technologies Inc. (CBOE CA:ABXX) (“Abaxx” or the “Company”), a financial software and market infrastructure company, majority shareholder of Abaxx Singapore Pte Ltd., the owner of Abaxx Commodity Exchange and Clearinghouse (individually, “Abaxx Exchange” and “Abaxx Clearing”), and producer of the SmarterMarkets™ Podcast, is pleased to announce that it has closed its previously announced bought deal financing (the “Offering”).

Key Points: 
  • TORONTO, March 28, 2024 (GLOBE NEWSWIRE) -- Abaxx Technologies Inc. (CBOE CA:ABXX) (“Abaxx” or the “Company”), a financial software and market infrastructure company, majority shareholder of Abaxx Singapore Pte Ltd., the owner of Abaxx Commodity Exchange and Clearinghouse (individually, “Abaxx Exchange” and “Abaxx Clearing”), and producer of the SmarterMarkets™ Podcast, is pleased to announce that it has closed its previously announced bought deal financing (the “Offering”).
  • The Company issued a total of 1,437,500 common shares (the “Common Shares”) on a bought deal basis at an offering price of C$13.00 per Common Share (the “Offering Price”), which includes 187,500 Common Shares issued pursuant to the exercise of an over-allotment option, in full, for gross proceeds of C$18,687,500.
  • The Offering was co-led by Canaccord Genuity Corp. and BMO Capital Markets, together with Cantor Fitzgerald Canada Corporation (collectively the “Underwriters”).
  • This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States.

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

Retrieved on: 
Thursday, March 28, 2024
Lewy body, Exercise, Patient, Research, Sale, Prospectus, Morgan Stanley, Unit, Series, Working capital, Dementia, CRVO, Security (finance)

BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders (the “Company”), today announced that it has entered into a definitive securities purchase agreement for a private placement to sell an aggregate of 2,532,285 units (the “Units”), each Unit comprised of (i) (A) one share of its common stock or (B) one pre-funded warrant to purchase shares of its common stock, and in each case, (ii) one Series A warrant to purchase shares of its common stock to a select group of institutional and accredited healthcare specialist investors in a private placement. A Unit comprised of one share of common stock and one Series A warrant shall have a purchase price of $19.745 and a Unit comprised of one pre-funded warrant and one Series A warrant shall have a purchase price of $19.744.

Key Points: 
  • The pre-funded warrants have an exercise price of $0.001 per share, will be immediately exercisable and will not expire.
  • The private placement is expected to close on or about April 1, 2024, subject to customary closing conditions.
  • The financing is being led by RA Capital Management and includes participation from other new institutional investors, including Armistice Capital, Special Situations Funds and Soleus Capital.
  • Morgan Stanley and Canaccord Genuity are acting as placement agents for the private placement.

Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 28, 2024
OTC Markets Group, Failure, Conference, Birth, Growth, Exercise, Table, Agile, Net, Woman, OTC, Therapy, GAAP, Administration, FDA, COGS, Clothing

Net revenue for the fourth quarter 2023 was $3.6 million, a 46% decrease from the third quarter 2023 net revenue of $6.7 million.

Key Points: 
  • Net revenue for the fourth quarter 2023 was $3.6 million, a 46% decrease from the third quarter 2023 net revenue of $6.7 million.
  • For the fourth quarter 2023, Twirla demand was 68,793 total cycles, a 7% decrease from the 74,325 total cycles reported for the third quarter 2023.
  • For the fourth quarter 2023, Twirla factory sales were 68,580 total cycles, an 8% decrease from the 74,424 total cycles reported for the third quarter 2023.
  • Fourth quarter 2023 operating expenses were $5.5 million, a decrease of 33% from the $8.2 million for the third quarter 2023.

Troilus Provides Operational Update

Retrieved on: 
Thursday, March 28, 2024
TLG, CAPEX, Exercise, Project, Gold, Copper, Publishing, FRA, Feasibility study, TSX

MONTREAL, March 28, 2024 (GLOBE NEWSWIRE) -- Troilus Gold Corp. (TSX: TLG; OTCQX: CHXMF; FRA: CM5R) (“Troilus” or the “Company”), provides an operational update related to the advancement of its gold-copper Troilus Project (“Troilus” or the “Project”), located in northcentral Quebec; one of the largest undeveloped gold equivalent deposits in North America.

Key Points: 
  • MONTREAL, March 28, 2024 (GLOBE NEWSWIRE) -- Troilus Gold Corp. (TSX: TLG; OTCQX: CHXMF; FRA: CM5R) (“Troilus” or the “Company”), provides an operational update related to the advancement of its gold-copper Troilus Project (“Troilus” or the “Project”), located in northcentral Quebec; one of the largest undeveloped gold equivalent deposits in North America.
  • The Feasibility Study for the Troilus Project is proceeding well, as the various components of the report approach finalization to create a cohesive picture of the potential future operation.
  • Justin Reid, CEO of Troilus, commented, “We see these exercises as a vote of confidence from some of our major shareholders.
  • These warrant exercises infuse cash into our treasury, strengthening our financial position as we progress Troilus towards a construction decision.”

Avalon GloboCare Extends Exclusivity Agreement to Distribute KetoAir Breathalyzer Device and AI-Enabled Software in North America, South America, United Kingdom and European Union

Retrieved on: 
Thursday, March 28, 2024
Health, Obesity, Algorithm, Apple, Exercise, Qi, Diabetes, AI, Google Play, European, FDA, Medical device

KetoAir™ is a pioneering breathalyzer device equipped with AI-enabled software, designed for ketogenic health management (United States FDA registration number: 3026284320).

Key Points: 
  • KetoAir™ is a pioneering breathalyzer device equipped with AI-enabled software, designed for ketogenic health management (United States FDA registration number: 3026284320).
  • Moreover, the AI nutritionist within the app offers personalized nutritional and exercise recommendations tailored to each user's health goals.
  • “We are excited to extend our exclusive distribution agreement for KetoAir™ with Qi Diagnostics,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare.
  • “KetoAir™ is the first breathalyzer on the market that uses an AI nutritionist bundled with a nanosensor-based breathalyzer for ketogenic health management.

Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 28, 2024
Q&A, Exercise, Patient, Pulmonary hypertension, Cardiovascular Research, Clinical trial, IP, Therapy, LINK, Research, Science, LEVEL, Public expenditure, Heart failure, Development, Tenax, Disease, KOL, TNX-102, First, Research and development, MPH, Cardiology, Conference, Patent, Doctor of Philosophy, Faculty, MBA, Levosimendan, THT, Feinberg School of Medicine, Pharmaceutical industry

We also made important progress in further expanding levosimendan’s U.S. intellectual property protections, securing the future commercial value of TNX-103.

Key Points: 
  • We also made important progress in further expanding levosimendan’s U.S. intellectual property protections, securing the future commercial value of TNX-103.
  • In February 2024, Tenax Therapeutics announced that the first patient had enrolled in the Phase 3 LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients) ( NCT05983250 ).
  • LINK TO REGISTER
    Tenax Therapeutics reported cash and cash equivalents of $9.8 million as of December 31, 2023.
  • Tenax Therapeutics reported a net loss for 2023 of $7.7 million, compared to a net loss of $11.0 million in 2022.

Greenridge Exploration Announces Appointment of Sean Hillacre to its Advisory Team

Retrieved on: 
Thursday, March 28, 2024
Option, Uranium, Exercise, Knowledge, GXP, University, Arrow, CDN, Oil

VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Greenridge Exploration Inc. (“Greenridge” or the “Company”) (CSE: GXP | FRA: HW3), is pleased to announce Sean Hillacre has joined Greenridge’s advisory team effective March 22, 2024.

Key Points: 
  • VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Greenridge Exploration Inc. (“Greenridge” or the “Company”) (CSE: GXP | FRA: HW3), is pleased to announce Sean Hillacre has joined Greenridge’s advisory team effective March 22, 2024.
  • Mr. Hillacre’s extensive experience and background will provide invaluable guidance for the planning and execution of exploration programs at the Company's Nut Lake Project.
  • Sean Hillacre, Advisor to the Company, commented, “I am thrilled to be joining the Greenridge team as an advisor, as the Company’s Nut Lake Project has significant potential for uranium discovery.
  • Russell Starr, Chief Executive Officer of the Company, commented, “We are excited to welcome Mr. Hillacre, whose extensive experience in the Uranium industry, particularly in the globally recognized Athabasca Basin region, brings invaluable expertise to our advisory team.

NCLA Fights Delegation of Government Power to Public Company Accounting Oversight Board

Retrieved on: 
Wednesday, March 27, 2024
Brett Kavanaugh, Congress, Dickinson Wright, Exercise, District court, Star, Complaint, Star Chamber, PCAOB, Constitution, Sarbanes, Government, NCLA, Audit

Washington, D.C., March 27, 2024 (GLOBE NEWSWIRE) -- Today, the New Civil Liberties Alliance filed a Complaint urging the U.S. District Court for the Southern District of Texas to declare that the Public Company Accounting Oversight Board is a private entity unlawfully exerting government power.

Key Points: 
  • Washington, D.C., March 27, 2024 (GLOBE NEWSWIRE) -- Today, the New Civil Liberties Alliance filed a Complaint urging the U.S. District Court for the Southern District of Texas to declare that the Public Company Accounting Oversight Board is a private entity unlawfully exerting government power.
  • Under Sarbanes-Oxley the Board is supposed to establish “fair procedures” but Congress did not provide an intelligible principle to guide writing them.
  • The Board has thus buried NCLA’s client, a small accounting firm, with a sixth “Accounting Board Demand” for reams of private firm documents.
  • The Board routinely punishes targets for “noncooperation” with Board investigative demands before they have any opportunity to challenge those demands in a court of law.

EMS is Transforming Conventional Fitness Training at SmartFit and its Franchises

Retrieved on: 
Wednesday, March 27, 2024
Health, Attention, Exercise, Risk, Research, Muscle fatigue, Muscle contraction, Electrode, Woman, Athlete, Injury, EMS, Rehabilitation, Dietary supplement

With celebrities like Liz Hurley, Heidi Klum, and Madonna endorsing its effectiveness, EMS training has piqued the curiosity of fitness enthusiasts worldwide, sparking a surge in interest and inquiries.

Key Points: 
  • With celebrities like Liz Hurley, Heidi Klum, and Madonna endorsing its effectiveness, EMS training has piqued the curiosity of fitness enthusiasts worldwide, sparking a surge in interest and inquiries.
  • Those utilizing EMS suits exhibited significant improvements in body circumference and cardiovascular function, hinting at the potential of EMS training to yield notable fitness gains.
  • Lara Oliveira, wife and mother of three children, spearheads SmartFit , the first EMS training fitness studio in Georgia, with a passion for revolutionizing the fitness landscape.
  • Inspired by her own struggles to juggle motherhood and fitness, Lara stumbled upon EMS training during a visit to her native Brazil in 2018.